⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Vibegron (GEMTESA)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-29 — Vibegron for ENergy Thinking and Resilience in Aging: 12-week randomized, double-blind, placebo-controlled trial (VENTURA-Aging) launched to test vibegron (a β3-adrenergic agonist approved for overactive bladder) for energy metabolism, cardiometabolic risk, and physical/cognitive function in middle-aged and older adults with obesity — trial registered, no results yet. [human-rct] (novelty: 3)
Open questions
Related
Contributing findings
Vibegron for ENergy Thinking and Resilience in Aging
29-sep-2026
novelty 3
per-area 3
strengthens